These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37469249)

  • 1. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
    Ticau S; Aldinc E; Polydefkis M; Adams D; Coelho T; Ueda M; Hale C; Vest J; Nioi P;
    Amyloid; 2024 Mar; 31(1):1-11. PubMed ID: 37469249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
    Adams D; Polydefkis M; González-Duarte A; Wixner J; Kristen AV; Schmidt HH; Berk JL; Losada López IA; Dispenzieri A; Quan D; Conceição IM; Slama MS; Gillmore JD; Kyriakides T; Ajroud-Driss S; Waddington-Cruz M; Mezei MM; Planté-Bordeneuve V; Attarian S; Mauricio E; Brannagan TH; Ueda M; Aldinc E; Wang JJ; White MT; Vest J; Berber E; Sweetser MT; Coelho T;
    Lancet Neurol; 2021 Jan; 20(1):49-59. PubMed ID: 33212063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D
    Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.
    Quan D; Obici L; Berk JL; Ando Y; Aldinc E; White MT; Adams D
    Amyloid; 2023 Mar; 30(1):49-58. PubMed ID: 36120830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D
    J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Gorevic P; Franklin J; Chen J; Sajeev G; Wang JCH; Lin H
    Expert Opin Pharmacother; 2021 Jan; 22(1):121-129. PubMed ID: 32892660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
    Ticau S; Sridharan GV; Tsour S; Cantley WL; Chan A; Gilbert JA; Erbe D; Aldinc E; Reilly MM; Adams D; Polydefkis M; Fitzgerald K; Vaishnaw A; Nioi P
    Neurology; 2021 Jan; 96(3):e412-e422. PubMed ID: 33087494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
    Brannagan TH; Coelho T; Wang AK; Polydefkis MJ; Dyck PJ; Berk JL; Drachman B; Gorevic P; Whelan C; Conceição I; Plante-Bordeneuve V; Merlini G; Obici L; Plana JMC; Gamez J; Kristen AV; Mazzeo A; Gentile L; Narayana A; Olugemo K; Aquino P; Benson MD; Gertz M;
    J Neurol; 2022 Dec; 269(12):6416-6427. PubMed ID: 35908242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.
    Lin KP; Yang CC; Lee YC; Lee MJ; Vest J; Sweetser MT; White MT; Badri P; Hsieh ST; Chao CC
    J Formos Med Assoc; 2024 Sep; 123(9):975-984. PubMed ID: 38548524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
    Schmidt HH; Wixner J; Planté-Bordeneuve V; Muñoz-Beamud F; Lladó L; Gillmore JD; Mazzeo A; Li X; Arum S; Jay PY; Adams D;
    Am J Transplant; 2022 Jun; 22(6):1646-1657. PubMed ID: 35213769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
    Adams D; Tournev IL; Taylor MS; Coelho T; Planté-Bordeneuve V; Berk JL; González-Duarte A; Gillmore JD; Low SC; Sekijima Y; Obici L; Chen C; Badri P; Arum SM; Vest J; Polydefkis M;
    Amyloid; 2023 Mar; 30(1):1-9. PubMed ID: 35875890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
    Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
    N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.
    Coelho T; Adams D; Conceição I; Waddington-Cruz M; Schmidt HH; Buades J; Campistol J; Berk JL; Polydefkis M; Wang JJ; Chen J; Sweetser MT; Gollob J; Suhr OB
    Orphanet J Rare Dis; 2020 Jul; 15(1):179. PubMed ID: 32641071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.
    Adams D; Suhr OB; Dyck PJ; Litchy WJ; Leahy RG; Chen J; Gollob J; Coelho T
    BMC Neurol; 2017 Sep; 17(1):181. PubMed ID: 28893208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
    Zhang X; Goel V; Attarwala H; Sweetser MT; Clausen VA; Robbie GJ
    J Clin Pharmacol; 2020 Jan; 60(1):37-49. PubMed ID: 31322739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
    Minamisawa M; Claggett B; Adams D; Kristen AV; Merlini G; Slama MS; Dispenzieri A; Shah AM; Falk RH; Karsten V; Sweetser MT; Chen J; Riese R; Vest J; Solomon SD
    JAMA Cardiol; 2019 May; 4(5):466-472. PubMed ID: 30878017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I
    Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.
    Brannagan TH; Wang AK; Coelho T; Waddington Cruz M; Polydefkis MJ; Dyck PJ; Plante-Bordeneuve V; Berk JL; Barroso F; Merlini G; Conceição I; Hughes SG; Kwoh J; Jung SW; Guthrie S; Pollock M; Benson MD; Gertz M;
    Eur J Neurol; 2020 Aug; 27(8):1374-1381. PubMed ID: 32343462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.